Personalized Neoantigen MRNA Vaccine(Nanjing Tianyinshan Hospital)

RGL-270

Report date: 2026/04/28 20:00:22

Base Information

Drug NamePersonalized Neoantigen MRNA Vaccine(Nanjing Tianyinshan Hospital)
Drug Alias NameRGL-270RGL270
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanjing Tianyinshan Hospital
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Tianyinshan HospitalGuangzhou Ruiling Pharmaceutical Co LtdShanghai Regenelead Therapies Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A